Meningococcal group b vaccine, multicomponent (4cmenb)
Brand: Bexsero®
PBAC's latest decision on Meningococcal group b vaccine, multicomponent (4cmenb): Recommended with restriction (2019). Considered for Active immunisation against invasive meningococcal disease (IMD) caused by Neisseria meningitidis group B strains in individuals from 2 months of age and older.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Infants and adolescents for active immunisation against invasive meningococcal disease caused by Neisseria meningitidis group B; includes catch-up programs for children under 2 years, Aboriginal and Torres Strait Islander people under 20 years, and people with medical conditions increasing IMD risk.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Other
Key trials
UK PHE Vaccination Program, Quebec Regional Vaccination Program, Portugal PT-BEST study, South Australia B Part of It study, V72_28, V72_28E1, V72_75
Comparator
no vaccine
Economic model
CUA
ICER note
Price information and specific ICER values are redacted throughout the document (indicated by quotation marks and asterisks).